Glatiramer Acetate Injection, Solution
Product Images NDC 0832-6084

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Glatiramer Acetate (NDC 0832-6084). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (1)

Illustration showing components related to injection administration, including a sharps disposal container, syringe in blister package, injection diary, alcohol wipes, and cotton balls. The items are arranged separately with labels identifying each component.*

FDA Label Image

Image Description (10)

An instructional illustration showing a hand administering a subcutaneous injection using a syringe. The needle is being inserted into the skin with an upward arrow indicating the direction of injection.*

FDA Label Image

Image Description (11)

An instructional illustration showing a person using two fingers to pinch the skin, typically demonstrating the preparation or technique for a subcutaneous injection.*

FDA Label Image

Image Description (12)

An illustration of a sharps disposal container with a biohazard symbol on the front, likely used for the safe disposal of needles and syringes associated with injectable medications.*

FDA Label Image

Image Description (2)

An instructional illustration depicting hands preparing a syringe with a vial or container, likely for subcutaneous injection. One hand holds the vial steady while the other inserts the needle into the vial. No specific product labeling is visible.*

FDA Label Image

Image Description (20mgcarton)

Packaging label for Glatiramer Acetate Injection 20 mg/mL, an injection solution for subcutaneous use. The label indicates the product is available in 30 single-dose pre-filled syringes, with the instruction for once daily use. Labeler is Upsher-Smith Laboratories, LLC. The label includes storage information, dosage directions, and a barcode.*

FDA Label Image

Image Description (3)

Illustration showing recommended subcutaneous injection sites for Glatiramer Acetate Injection. It highlights the abdomen (avoiding about 2 inches around the belly button), back of hips and arms (fleshy areas of upper hips and upper back portion of arms), upper back portion of arms, and thighs (about 2 inches above the knee and 2 inches below the groin).*

FDA Label Image

Image Description (4)

An instructional illustration showing a person using their hand to apply a patch or prepare an injection site on their abdomen, likely demonstrating the subcutaneous injection technique relevant to Glatiramer Acetate Injection.*

FDA Label Image

Image Description (40mgcarton)

Packaging label for Glatiramer Acetate Injection 40 mg/mL, a subcutaneous injection solution by Upsher-Smith Laboratories, LLC. The label indicates the product contains 12 single-dose pre-filled syringes and is intended for use three times a week. Instructions include dispensing a medication guide to each patient. The label also provides storage instructions and manufacturer details.*

FDA Label Image

Image Description (5)

An instructional three-panel diagram illustrating the proper technique for handling a syringe. The first panel shows a hand holding the syringe upright, the second panel shows the other hand removing a protective cap from the needle, and the third panel shows the syringe held ready for injection with the cap discarded. No text is visible.*

FDA Label Image

Image Description (6)

An instructional illustration showing a hand pinching the skin, demonstrating the technique for preparing a subcutaneous injection site. The hand is depicted from the side with fingers grasping skin folds.*

FDA Label Image

Image Description (7)

Illustration showing a person administering a subcutaneous injection in the thigh. The image depicts the injection technique using a syringe for glatiramer acetate injection, solution.*

FDA Label Image

Image Description (8)

An instructional illustration depicting the administration of a subcutaneous injection. One hand is holding a syringe positioned at the thigh, while the other hand is supporting the area for injection. This aligns with the subcutaneous route of Glatiramer Acetate Injection, solution.*

FDA Label Image

Image Description (9)

An instructional illustration showing a hand administering a subcutaneous injection using a syringe. The syringe is held perpendicular to the skin surface, with an arrow indicating the downward insertion motion. This image likely demonstrates the proper technique for Glatiramer Acetate Injection administration.*

FDA Label Image

Image Description (A)

A line graph comparing the percentage of second exacerbation over time between Glatiramer Acetate Injection and a placebo. The x-axis shows days up to 1080, and the y-axis shows second exacerbation percentage up to 65%. The graph indicates a lower rate of exacerbation in the Glatiramer Acetate Injection group. Statistical values shown include p = 0.0005 and hazard ratio of 0.55.*

FDA Label Image

Image Description (B)

A line graph showing the cumulative median number of enhancing lesions over 9 months for Glatiramer Acetate Injection and placebo groups. The x-axis represents time in months, and the y-axis represents the cumulative number of lesions. Two lines compare Glatiramer Acetate Injection (gray) and placebo (black) trends over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.